Stockscreener 앱 받기
1.22
2.66%
-0.04
전일 마감가:
$1.26
열려 있는:
$1.25
하루 거래량:
56,942
Relative Volume:
0.22
시가총액:
$22.08M
수익:
-
순이익/손실:
$-8.29M
주가수익비율:
-1.7429
EPS:
-0.7
순현금흐름:
$-6.47M
1주 성능:
-3.43%
1개월 성능:
-19.84%
6개월 성능:
-26.11%
1년 성능:
-11.12%
1일 변동 폭
$1.21
$1.27
1주일 범위
$1.16
$1.29
52주 변동 폭
$0.94
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
명칭
NanoViricides Inc
전화
203-937-6137
주소
1 Controls Drive, Shelton, CT
NNVC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.227 | 22.68M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.20 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.25 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.68 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
909.10 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.34 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2015-02-11 | 개시 | Midtown Partners | Strong Buy |
NanoViricides Inc 주식(NNVC)의 최신 뉴스
What drives NanoViricides Inc stock priceAnalyst Downgrades & Free Superior Stock Performance - earlytimes.in
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd - St. Cloud Times
NanoViricides Holds 2025 Annual Stockholders Meeting - TipRanks
NanoViricides Dual Track Clinical Strategy Explained by a Research ReportBroad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses - Livingston Daily
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - The Marion Star
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value - Canton Daily Ledger
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - Bluffton Today
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - York Daily Record
Why NanoViricides Inc. (NV3P) stock stays resilient2025 Stock Rankings & Precise Swing Trade Entry Alerts - newser.com
Why NanoViricides Inc. stock stays resilientPortfolio Value Report & Technical Confirmation Trade Alerts - newser.com
Will NanoViricides Inc. stock recover faster than industryJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - newser.com
Why NanoViricides Inc. stock is trending on social media2025 Market Overview & Safe Entry Point Identification - newser.com
Will NanoViricides Inc. stock continue upward momentumJuly 2025 PreEarnings & Free Fast Entry Momentum Trade Alerts - newser.com
Can NanoViricides Inc. (NV3P) stock ride next bull market cycleWeekly Trade Analysis & Weekly High Conviction Ideas - newser.com
Is NanoViricides Inc. (NV3P) stock supported by free cash flow2025 Market Outlook & Growth Focused Investment Plans - newser.com
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - Erie Times-News
Will NanoViricides Inc. stock sustain bullish trend into 20252025 Year in Review & Technical Confirmation Trade Alerts - newser.com
Is NanoViricides Inc. (NV3P) stock a good hedge against inflationTrade Volume Report & Weekly Setup with ROI Potential - newser.com
Will NanoViricides Inc. stock boost dividends furtherMarket Risk Summary & Community Consensus Picks - newser.com
Is NanoViricides Inc. stock a buy before product launchesJuly 2025 Trends & Free Real-Time Market Sentiment Alerts - newser.com
Published on: 2025-11-19 20:46:00 - newser.com
Why institutional investors increase stakes in NanoViricides Inc. (NV3P) stockEarnings Risk Report & Risk Controlled Swing Trade Alerts - newser.com
How NanoViricides Inc. stock trades after earnings2025 Year in Review & Expert-Curated Trade Recommendations - newser.com
NanoViricides Inc (NNVC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.30%
0.74%
자본화:
|
볼륨(24시간):